Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Luzu (luliconazole) is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum in patients 18 years of age and older.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• The combination of CO₂ laser therapy with topical agents, including luliconazole, increased efficacy for onychomycosis treatment by 5.38-fold compared to topical agents alone (OR 5.38; 95% CI: 3.20-9.04; p < 0.00001) and improved mycological clearance rates and satisfaction (OR 4.56; 95% CI: 2.78-7.49; p < 0.00001).
• Luliconazole 5% solution may increase mycological cure compared to the vehicle, though its effect on complete cure is uncertain, with a reported RR of 1.39 (95% CI: 0.98-1.97; very low-quality evidence).
• Efinaconazole 10% solution is more effective than the vehicle in achieving complete cure (RR 3.54; 95% CI: 2.24-5.60; high-quality evidence) and clinical cure (RR 3.07; 95% CI: 2.08-4.53; high-quality evidence), and is likely more effective in achieving mycological cure (RR 2.31; 95% CI: 1.08-4.94; moderate-quality evidence).
• Luliconazole 5% solution may have little or no difference in adverse events compared to the vehicle (RR 1.02; 95% CI: 0.90-1.16; low-quality evidence), with common adverse events including dry skin, paronychia, eczema, and hyperkeratosis, which generally improved or resolved post-treatment.
• Efinaconazole 10% solution is associated with a slightly higher risk of adverse events, such as dermatitis and vesicles (RR 1.10; 95% CI: 1.01-1.20; high-quality evidence), while tavaborole 5% solution likely has a higher risk of application site reactions (RR 3.82; 95% CI: 1.65-8.85; moderate-quality evidence).
• There is no population types or subgroups information available in the reviewed studies.